Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
CG-806 for B-cell Tumors
CG-806 for Myeloid Tumors
APTO-253
Posters & Presentations
Clinical Trials
Overview
CG-806 for CLL & NHL
CG-806 for AML
APTO-253 for AML & MDS
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Careers
Contact
Posters & Presentations
Product Pipeline
Product Pipeline
Overview
CG-806 for B-cell Tumors
CG-806 for Myeloid Tumors
APTO-253
Posters & Presentations
All
Poster
Presentation
June 11, 2021
Presentation
Aptose Corporate Update at EHA 2021
Aptose Corporate Update at EHA 2021:
View Presentation
June 11, 2021
Poster
2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies
2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies:
View Poster
June 11, 2021
Poster
2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS
2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS:
View Poster
June 2, 2021
Presentation
Aptose Biosciences Inc Corporate Presentation June 2021
Aptose Biosciences Inc Corporate Presentation June 2021:
View Presentation
December 6, 2020
Presentation
Aptose Corporate Update at ASH 2020
Aptose Corporate Update at ASH 2020:
View Presentation
December 6, 2020
Poster
2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL
2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL :
View Poster
December 5, 2020
Poster
2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS
2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS:
View Poster
June 22, 2020
Poster
2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas
2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas:
View Poster
June 12, 2020
Poster
2020 EHA Poster - Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with R/R CLL/SLL or NHL
2020 EHA Poster - Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with R/R CLL/SLL or NHL:
View Poster
1
2
3
4
5
Next